Clinical outcomes of potential high responders after individualized FSH dosing based on anti-Müllerian hormone and body weight
| Autor: | Bjarke Mirner Klein, Enrico Papaleo, Hana Visnova, Bernadette Mannaerts, Katarzyna Kozioł, Fernando Sánchez Martin |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
endocrine system
Pregnancy medicine.medical_specialty High responder biology business.industry Urology Obstetrics and Gynecology Anti-Müllerian hormone Follitropin alfa medicine.disease Body weight Reproductive Medicine medicine biology.protein Dosing Ovarian reserve business Developmental Biology Hormone |
| Zdroj: | Reproductive BioMedicine Online. 43:1019-1026 |
| ISSN: | 1472-6483 |
| Popis: | Research question How does the efficacy and safety of individualized follitropin delta dosing compare with conventional dosing for ovarian stimulation in potential high responders? Design Retrospective analysis of 153 potential high responders identified on the basis of baseline serum anti-Mullerian hormone (AMH) levels above 35 pmol/l, who were originally randomized to an individualized fixed dose of follitropin delta based on AMH and body weight (n = 78) or to a daily starting dose of 150 IU follitropin alfa (n = 75). Results At the end of stimulation, patients treated with individualized follitropin delta or conventional follitropin alfa had 12.1 ± 7.0 and 18.3 ± 7.0 (P Conclusions Treatment with individualized follitropin delta provides an improved efficacy–safety balance in women with high ovarian reserve, as it normalizes the ovarian response and decreases the risk of OHSS without compromising the chance of pregnancy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect